Total Funding
77
64
Total FundingSeries B raised
Growth Score 77 in past quarter
-4 pts
Heat Score 64 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
26486
Our purpose is to make every pregnancy around the world safer.
- Richard Colvin: Global Head of Research and DevelopmentPast Role: Novartis Institutes for Biomedical Research, Executive Director, Senior Translational Medicine Expert
- Thomas Scott Johnson: CEO and Co-FounderPast Role: The Medicines, Chief Medical Advisor
About the Company
Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.